Evidence for treating rheumatoid arthritis to target: Results of a systematic literature search update

Annals of the Rheumatic Diseases

Volumn 75, Issue 1, 2016, Pages 16-22

  Stoffer, Michaela A ^a,b   Schoels, Monika M ^a   Smolen, Josef S ^a   Aletaha, Daniel ^a   Breedveld, Ferdinand C ^c   Burmester, Gerd ^d   Bykerk, Vivian ^e   Dougados, Maxime ^f   Emery, Paul ^g   Haraoui, Boulos ^h   Gomez Reino, Juan ⁱ   Kvien, Tore K ^j   Nash, Peter ^k   Navarro Compán, Victoria ^c,l   Scholte Voshaar, Marieke ^m   Van Vollenhoven, Ronald ⁿ   Van Der Heijde, Désirée ^c   Stamm, Tanja A ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b General Hospital Elisabethinen Linz   (Austria)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f Hospital for Special Surgery ^*  (France)

^g UNIVERSITY OF LEEDS   (United Kingdom)

^h UNIVERSITÉ DE MONTRÉAL   (Canada)

ⁱ UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^j DIAKONHJEMMET HOSPITAL   (Norway)

^k UNIVERSITY OF QUEENSLAND   (Australia)

^l HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^m UNIVERSITY OF TWENTE   (Netherlands)

ⁿ KAROLINSKA INSTITUTE   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; METHOTREXATE; ANTIRHEUMATIC AGENT;

ARTICLE; CARDIOVASCULAR RISK; COMORBIDITY; DAS28; DISEASE ASSESSMENT; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PRODUCTIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SELF EVALUATION; SYSTEMATIC REVIEW; TREAT TO TARGET; TREATMENT OUTCOME; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL (TOPIC); DIAGNOSTIC IMAGING; EVIDENCE BASED MEDICINE; PATHOPHYSIOLOGY; PATIENT CARE PLANNING; RADIOGRAPHY; SEVERITY OF ILLNESS INDEX;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; COMORBIDITY; EVIDENCE-BASED MEDICINE; HUMANS; PATIENT CARE PLANNING; RADIOGRAPHY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84954313769     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-207526     Document Type: Article

References (33)

1. van der Heijde DM, van 't Hof M, van Riel PL, et al. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20:579-81.
2. Prevoo ML, van 't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
3. Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 2003;42:244-57.
4. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
5. Aletaha D, Nell VP, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796-806.
6. Schoels M, Knevel R, Aletaha D, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 2010;69:638-43.
7. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Kerstens PJ, et al. DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. Ann Rheum Dis 2010;69:65-9.
8. Soubrier M, Lukas C, Sibilia J, et al. Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort. Ann Rheum Dis 2011;70:611-15.
9. van Eijk IC, Nielen MM, van der Horst-Bruinsma I, et al. Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial. Rheumatology 2012;51:686-94.
10. Schipper LG, Vermeer M, Kuper HH, et al. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. Ann Rheum Dis 2012;71:845-50.
11. Pope JE, Haraoui B, Rampakakis E, et al. Treating to a target in established active rheumatoid arthritis patients receiving a tumor necrosis factor inhibitor: results from a real-world cluster-randomized adalimumab trial. Arthritis Care Res 2013;65:1401-9.
12. Vermeer M, Kievit W, Kuper HH, et al. Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry. BMC Musculoskelet Disord 2013;14:350.
13. Aletaha D, Funovits J, Breedveld FC, et al. Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. Arthritis Rheum 2009;60:1242-9.
14. Smolen JS, Han C, van der Heijde DM, et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 2009;68:823-7.
15. Provan SA, Semb AG, Hisdal J, et al. Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study. Ann Rheum Dis 2011;70:812-17.
16. Solomon DH, Kremer J, Curtis JR, et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 2010;69:1920-5.
17. Sciré CA, Lunt M, Marshall T, et al. Early and sustained remission is associated with improved survival in patients with inflammatory polyarthritis: Results from the norfolk arthritis register. Ann Rheum Dis 2013;71:95-6.
18. Gullick NJ, Oakley SP, Zain A, et al. Goal-directed therapy for RA in routine practice is associated with improved function in patients with disease duration up to 15 years. Rheumatology 2012;51:759-61.
19. Radner H, Smolen JS, Aletaha D. Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. Arthritis Res Ther 2014;16:R56.
20. Rantalaiho V, Kautiainen H, Korpela M, et al. Physicians' adherence to tight control treatment strategy and combination DMARD therapy are additively important for reaching remission and maintaining working ability in early rheumatoid arthritis: a subanalysis of the FIN-RACo trial. Ann Rheum Dis 2014;73:788-90.
21. Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013;381:918-29.
22. Dirven L, van den Broek M, van Groenendael JH, et al. Prevalence of vertebral fractures in a disease activity steered cohort of patients with early active rheumatoid arthritis. BMC Musculoskelet Disord 2012;13:125.
23. Krishnan E, Lingala B, Bruce B, et al. Disability in rheumatoid arthritis in the era of biological treatments. Ann Rheum Dis 2012;71:213-18.
24. Crowson CS, Liao KP, Davis JM III, et al. Rheumatoid arthritis and cardiovascular disease. Am Heart J 2013;166:622-8 e621.
25. Pope J, Thorne C, Cividino A, et al. Effect of rheumatologist education on systematic measurements and treatment decisions in rheumatoid arthritis: the metrix study. J Rheumatol 2012;39:2247-52.
26. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
27. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016;75:3-15.
28. Thiele K, Huscher D, Bischoff S, et al. Performance of the 2011 ACR/EULAR preliminary remission criteria compared with DAS28 remission in unselected patients with rheumatoid arthritis. Ann Rheum Dis 2013;72:1194-9.
29. Vermeer M, Kuper HH, Moens HJ, et al. Sustained beneficial effects of a protocolized treat-to-target strategy in very early rheumatoid arthritis: three-year results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort. Arthritis Care Res 2013;65:1219-26.
30. Sakellariou G, Scire CA, Verstappen SM, et al. In patients with early rheumatoid arthritis, the new ACR/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis. Ann Rheum Dis 2013;72:245-9.
31. Balsa A, de Miguel E, Castillo C, et al. Superiority of SDAI over DAS-28 in assessment of remission in rheumatoid arthritis patients using power Doppler ultrasonography as a gold standard. Rheumatology 2010;49: 683-90.
32. Dale J SA, McInnes IB, Porter D. Targeting ultrasound remission in early rheumatoid arthritis-results of the taser study. Arthritis Rheum 2013;65 (Suppl):338-9.
33. Dale J, Purves D, McConnachie A, et al. Tightening up? Impact of musculoskeletal ultrasound disease activity assessment on early rheumatoid arthritis patients treated using a treat to target strategy. Arthritis Care Res 2014;66:19-26.